Neon Looks To Pioneer Neoantigen Space
This article was originally published in The Pink Sheet Daily
Executive Summary
With Third Rock partners in executive roles, a personalized vaccine will go into clinical development in 2016, but Neon also plans to develop a personalized T-cell therapy and off-the-shelf vaccines and T-cell therapies based on groundbreaking neoantigen biology.